Everest Medicines (HKG:1952) said substantial shareholder Wei Fu purchased 860,000 shares in the open market on March 27 for about HK$32.7 million, according to a Monday Hong Kong bourse filing.

The shares were acquired at an average price of about HK$38.12 each through his controlled entity, the filing said.